Table 2.

Product profile for a human CCHF vaccine.

Feature	Reason
Induction of humoral and cellular responses	Only vaccine approaches which induce both arms of the adaptive immune system have demonstrated protection against CCHFV challenge
Authentic expression of gene product	The antigen exposed to the immune system needs to be identical to the target virus to optimise linear and non-linear epitope recognition
Acceptable ‘Costs of Goods’ profile	Cost will be a key factor in uptake by authorities in endemic regions where healthcare finances are limited
Manufacturing capability	The vaccine should be able to be produced rapidly in outbreak conditions and in sufficient quantities for immunisation of at risk groups in endemic regions
Thermostable	CCHFV is endemic in countries that experience high temperatures. A thermostable vaccine would remove the logistics and extra costs associated with maintaining a cold chain
Safety profile	A vaccine based on similar technologies with existing safety data is more likely to be successful in clinical trials and faster to license
Few doses required	Vaccine uptake will be increased if multiple boosters are not required